PAMU
BEAM icon

Pictet Asset Management (UK)’s Beam Therapeutics BEAM Stock Holding History

Pictet Asset Management (UK)’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$25M Buy
194,316
+2,159
+1% +$172K 0.03% 481
2021
Q1 		$15.4M Sell
192,157
-67,299
-26% -$6.4M 0.02% 558
2020
Q4 		$21.2M Buy
+259,456
New +$12.8M 0.03% 468

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management (UK)'s BEAM Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Beam Therapeutics (BEAM) stake by 1.1% in Q2 2021, buying an estimated $172K and bringing the position to 194,316 shares worth $25M. The position accounts for 0.03% of the portfolio, ranked #481.

Pictet Asset Management (UK) first reported a position in BEAM in Q4 2020 and has held it in 3 quarters since. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Pictet Asset Management (UK) held 194,316 shares of Beam Therapeutics worth $25M as of Q2 2021.
  • Pictet Asset Management (UK) bought 2,159 Beam Therapeutics shares in Q2 2021, an estimated $172K.
  • Beam Therapeutics made up 0.03% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #481 holding.
  • Pictet Asset Management (UK) first reported a position in Beam Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.